相关实验视频

Updated: May 20, 2025

Isolation and Expansion of Cytotoxic Cytokine-induced Killer T Cells for Cancer Treatment

Isolation and Expansion of Cytotoxic Cytokine-induced Killer T Cells for Cancer Treatment

Published on: January 24, 2020

准interleukin-2-可诱导的T细胞激酶可以改善免疫介导的无形性贫血

Weiwang Li^1,2,3, Yu Lian⁴, Lele Zhang^1,2,3

¹State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, 300020, China.

Cancer immunology, immunotherapy : CII

|April 29, 2025

概括

在无形性贫血 (AA) 中研究IL-2诱导的T细胞激酶 (ITK) 发现ITK水平升高. 抑制ITK显示为AA患者的新治疗策略,改善治疗结果和生存率.

科学领域:

免疫学免疫学免疫学
血液学血液学血液学
药理学药理学是指药理学的学科.

背景情况:

无形性贫血 (AA) 的治疗依赖于干细胞移植和免疫抑制疗法 (IST).
传染病具有显著的风险和高耐药性或复发性疾病率 (30-50%),需要新的治疗方法.
在AA病理生理学中IL-2诱导T细胞激酶 (ITK) 的作用在很大程度上尚未被探索.

研究的目的:

调查ITK在无塑性贫血中的作用.
评估ITK抑制在AA中的治疗潜力.

主要方法:

从AA患者和小鼠模型的T细胞中量化化ITK水平.
在捐赠小鼠中使用ITK抑制剂或有条件耗尽ITK.
在AA小鼠模型中评估骨髓细胞性,周围血液计数和生存率.
分析了T细胞透和炎症性细胞因子的概况.

主要成果:

在AA患者和模型的T细胞中观察到高酸化ITK水平.
ITK抑制或耗尽改善了骨髓低成形和细胞衰减.
用ITK抑制剂治疗延长了AA小鼠的生存率.
抑制ITK可以减少T细胞的透,并抑制炎症性细胞因子分泌.

结论:

ITK在无塑性贫血的病理生理学中发挥着重要作用.
用抑制剂向ITK是AA的一种有前途的新疗法策略.

关键词:

无形成性贫血是什么?由IL-2诱导的T细胞激酶酶.的T淋巴细胞.有针对性的治疗.

更多相关视频

Generation of Induced Pluripotent Stem Cells from Human Melanoma Tumor-infiltrating Lymphocytes

Generation of Induced Pluripotent Stem Cells from Human Melanoma Tumor-infiltrating Lymphocytes

Published on: November 11, 2016

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Cell-mediated Immune Responses

Cell-mediated Immune Responses